Thus, accurate incidence rates of EGFR and KRAS mutations are critical to reckon the effectiveness of molecular-targeted agents as personalized treatment for advanced NSCLC and mCRC patients in any given population. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.